Search details
1.
A polygenic risk score predicts atrial fibrillation in cardiovascular disease.
Eur Heart J
; 44(3): 221-231, 2023 01 14.
Article
in English
| MEDLINE | ID: mdl-35980763
2.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Article
in English
| MEDLINE | ID: mdl-35394821
3.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Article
in English
| MEDLINE | ID: mdl-35510542
4.
Curalin supplement for patients with type 2 diabetes mellitus.
Diabetes Metab Res Rev
; 39(4): e3624, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36797773
5.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Article
in English
| MEDLINE | ID: mdl-34427295
6.
Drug Therapies for Diabetes.
Int J Mol Sci
; 24(24)2023 Dec 05.
Article
in English
| MEDLINE | ID: mdl-38138975
7.
Obesity in late adolescence and incident type 1 diabetes in young adulthood.
Diabetologia
; 65(9): 1473-1482, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35665825
8.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Circulation
; 143(5): 470-478, 2021 02 02.
Article
in English
| MEDLINE | ID: mdl-33185476
9.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 380(4): 347-357, 2019 01 24.
Article
in English
| MEDLINE | ID: mdl-30415602
10.
Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: Analyses from a National Diabetes Registry.
Diabetes Metab Res Rev
; 38(1): e3485, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34233382
11.
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Diabetologia
; 64(6): 1226-1234, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33611623
12.
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Circulation
; 141(15): 1227-1234, 2020 04 14.
Article
in English
| MEDLINE | ID: mdl-31983236
13.
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation
; 142(8): 734-747, 2020 08 25.
Article
in English
| MEDLINE | ID: mdl-32795086
14.
From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Cardiovasc Diabetol
; 20(1): 92, 2021 04 28.
Article
in English
| MEDLINE | ID: mdl-33910583
15.
NAFLD in type 2 diabetes mellitus: Still many challenging questions.
Diabetes Metab Res Rev
; 37(2): e3386, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32677717
16.
Five years into the Israeli National Diabetes Program - are we on the right track?
Diabetes Metab Res Rev
; 37(6): e3421, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33175454
17.
Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes.
Diabetes Metab Res Rev
; 37(5): e3398, 2021 07.
Article
in English
| MEDLINE | ID: mdl-32852883
18.
The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status.
Diabetes Metab Res Rev
; 37(6): e3420, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33137237
19.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Diabetes Obes Metab
; 23(1): 29-38, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32844557
20.
[DIABETES - PRESENT AND FUTURE].
Harefuah
; 160(10): 634-637, 2021 Oct.
Article
in Hebrew
| MEDLINE | ID: mdl-34689431